MyoKardia reclaims US royalty rights to heart drugs, completing conscious uncoupling from Sanofi
In January, MyoKardia disclosed that Sanofi was walking away from their heart drug partnership forged in 2014. On Thursday, the San Francisco-based biotech said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
